Cingulate, Inc. (CING)
5.34
+0.15
(+2.89%)
USD |
NASDAQ |
Sep 09, 10:55
Cingulate Shareholders Equity (Quarterly) : 23.47M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 23.47M |
| March 31, 2026 | 18.86M |
| December 31, 2025 | 2.509M |
| September 30, 2025 | 3.474M |
| June 30, 2025 | 5.512M |
| March 31, 2025 | 5.931M |
| December 31, 2024 | 7.456M |
| September 30, 2024 | 12.04M |
| June 30, 2024 | 3.084M |
| Date | Value |
|---|---|
| March 31, 2024 | 3.216M |
| December 31, 2023 | -6.869M |
| September 30, 2023 | -0.0963M |
| June 30, 2023 | -6.098M |
| March 31, 2023 | 0.0816M |
| December 31, 2022 | 3.882M |
| September 30, 2022 | 8.366M |
| June 30, 2022 | 12.18M |
| March 31, 2022 | 16.02M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 597.21M |
| Corcept Therapeutics, Inc. | 705.78M |
| Veru, Inc. | 28.38M |
| Johnson & Johnson | 84.97B |
| Eli Lilly & Co. | 33.88B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 33.07M |
| Total Liabilities (Quarterly) | 9.599M |
| Debt to Equity Ratio | 0.2681 |
| Current Ratio | 3.50 |
| Net Debt Paydown Yield | -0.32% |